Loading current stock analysis…
Loading current stock analysis…
India
As of 18 Sept 2026, 03:30 pm
For the quarter ended June 30, 2026, Divi's Laboratories reported consolidated total income of ₹3,144 crores and profit after tax of ₹902 crores. These results were discussed during an earnings conference call held on August 1, 2026.
On August 26, 2026, K. Sridevi, an immediate relative of a promoter, sold 200 equity shares on the NSE for ₹1,770,000. Following this sale, she held 3,100 shares.
As of September 18, 2026, Divi's Laboratories has shown varied returns across different periods. The company's year-to-date (YTD) return was 0.48, and its return over the last 6 months was 0.53. Over a longer period, the return over the last year was 0.53. Shorter-term returns include 0.09 for the last 3 months and 0.01 for the last month.
Technical indicators suggest a bullish trend for Divi's Laboratories. On a daily timeframe, the Supertrend indicator is bullish, and the Exponential Moving Average (EMA) 20 slope is positive (103.59). Similarly, on a weekly timeframe, the Supertrend direction is bullish, with a positive EMA 20 slope of 811.9. The monthly trend also shows a bullish Supertrend direction.
As of 18 Sept 2026, 03:30 pm
Showing 3 of 14 candles
Recent drawdown and price variability remain within the producer's contained-risk thresholds.
The session opened materially below the previous close, indicating a sharp repricing at the open.
The price gap may increase short-term downside uncertainty and warrants review of the underlying context.
Trading volume was unusually high, but the closing price did not show a clear directional move.
This indicates increased participation without a clear directional signal.
Trading activity was substantially higher than usual and the price closed higher.
This may reflect stronger-than-usual market participation; follow-through and relevant company or market news merit review.
Latest complete financial results for Q1 FY2027 and comparative quarterly trends.
| Metric | Q1 FY2026-27(Latest) | Q4 FY2025-26 | Q3 FY2025-26 | Q2 FY2025-26 | Q1 FY2025-26 |
|---|---|---|---|---|---|
| Profit Before Tax | ₹1,180 crore | PEAK₹3,388 crore | ₹780 crore | ₹912 crore | ₹733 crore |
| Tax Expense | ₹278 crore | PEAK₹820 crore | ₹197 crore | ₹223 crore | ₹188 crore |
| Profit Loss For Period | ₹902 crore | PEAK₹2,568 crore | ₹583 crore | ₹689 crore | ₹545 crore |
| Revenue From Operations | ₹3,080 crore | PEAK₹10,560 crore | ₹2,604 crore | ₹2,715 crore | ₹2,410 crore |
| Finance Costs | ₹6 crore | PEAK₹23 crore | ₹6 crore | ₹8 crore | ₹3 crore |
| Other Expenses | ₹431 crore | PEAK₹1,584 crore | ₹402 crore | ₹400 crore | ₹385 crore |
Basic and diluted earnings per share were each ₹33.95, compared with ₹20.49 in Q1 FY2026, a 65.7% increase. The basic and diluted figures being identical suggests there are no outstanding instruments with a dilutive effect.
Revenue and profit for the quarter ended 30 June 2026 were materially higher than in the year-ago period, with profit growing faster than revenue and pushing margins higher. The steep sequential decline from the prior quarter reflects the outsized scale of that period and not an indication of weakening performance. Other expenses increased at a rate well below revenue growth, and the effective tax rate was slightly lower year-on-year.
Exchange disclosures and regulatory announcements for Divi's Laboratories.
Divi's Laboratories Limited published newspaper advertisements on September 12, 2026, in Financial Express (all editions) and Andhra Prabha (Hyderabad edition) regarding a special window for the transfer and dematerialisation of physical shares, as required by SEBI Circular HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated January 30, 2026.
DIVISLAB|Divi's Laboratories Limited|Original|Regulation 7 (2)|IT_2132_WebXMLFile_20260831_110842619.xml|IT_2132_20260831_110842670_WEB.html|5150|22290|-
On August 26, 2026, K. Sridevi, an immediate relative of a promoter of Divi's Laboratories Limited, sold 200 equity shares on the NSE at a value of INR 1,770,000 through a market sale. Post-disposal, she held 3,100 shares, representing 0% shareholding.
DIVISLAB|Divi's Laboratories Limited|Original|Regulation 7 (2)|IT_2132_WebXMLFile_20260821_111254441.xml|IT_2132_20260821_111254480_WEB.html|5142|22282|-
Divi's Laboratories Limited held an earnings conference call on August 1, 2026, to discuss results for the quarter ended June 30, 2026. The company reported consolidated total income of ₹3,144 crores and profit after tax of ₹902 crores for Q1 FY27. Management discussed progress on custom synthesis projects, peptide business expansion, and the role of Unit 3 in their manufacturing network. Challenges related to solvent costs and global logistics were also addressed.
Divi's Laboratories Limited uploaded the transcript of its earnings or quarterly call on August 6, 2026, at 14:47:00. The call concluded on August 1, 2026, at 15:00:00, following prior intimation to the exchange on July 24, 2026. The transcript is available for review at https://www.divislabs.com/investor-relations/statutory-communication/.
Divi's Laboratories Limited published its unaudited financial results for the quarter ended June 30, 2026, on August 2, 2026, in the Financial Express and Andhra Prabha newspapers.
Divi's Laboratories Limited's Board of Directors approved unaudited financial results for the quarter ended June 30, 2026, reporting consolidated total income of ₹3,144 crores and profit after tax of ₹902 crores. The board also approved the appointment of Mr. B. Vara Prasad and Mr. J. Srinivasa Rao as Senior Management Personnel, effective August 01, 2026.
Recent market and company developments associated with Divi's Laboratories.
Capitalmind Flexi Cap Fund made five fresh additions and completely exited five stocks from its portfolio in August, while keeping its exposure unchanged in 27 stocks. The fund had 32 stocks across 17 sectors, with healthcare accounting for the largest allocation. Heres a look at the stocks added and exited, sector allocation and the funds performance since inception.
Meet India’s highest-paid CEOs in FY26. From Persistent Systems' Sandeep Kalra crossing ₹388 crore to Angel One's Ambarish Kenghe posting a 10,000% spike, here are the 10 highest-paid business leaders in FY26 and their compensation packages.
Trade Spotlight
If grey market trends are anything to go by, the stock could make a strong debut with a premium of around 19% over its issue price. The grey market premium (GMP) currently stands at ₹185, indicating an estimated listing price of around ₹1,173 per share, compared with the IPO price of ₹988.
The employee reservation portion led with 1.19 times subscription; Retail Individual Investors subscription at 0.82 times, NII category is at 0.86 times. QIB remained the weakest segment at 0.35 times
Symbiotec Pharmalab plans a ₹150 crore IPO to repay debt and expand operations. The company holds a global leadership position in corticosteroid and steroidal-hormone APIs. Its revenue primarily comes from international markets, with Europe being a significant contributor. Financials show steady revenue and EBITDA growth over recent years. Investors with a high-risk appetite may consider this long-term opportunity.
India Inc's Q1 performance shows strong revenue growth, defying initial gloom, despite challenges from rising input costs.
Sandeep Bhatia of Macquarie Capital breaks down this quarter's earnings surprise across large and small caps, his top picks in autos and private banking, and a possible rotation between technology and power stocks tied to global AI valuations over the next 18 months.
Comprehensive Section Breakdown for Divi's Laboratories
Strategic Vision: Manufactures active pharmaceutical ingredients, intermediates, and nutraceuticals.
• Expertise in handling high-potency compounds and executing high-energy reactions.
• Large-scale production capabilities for APIs.
• Established global supply chain with long-term partnerships.
• Adherence to stringent global regulatory standards.
Divi’s Laboratories Limited reported revenue from operations of ₹3,080 crore for the quarter ended 30 June 2026, a 27.8% increase from ₹2,410 crore in the same quarter a year ago. Profit before tax rose 60.9% to ₹1,180 crore, and profit after tax increased 65.5% to ₹902 crore. The quarter follows an unusually large preceding quarter (Q4 FY2026), which delivered revenue of ₹10,560 crore.
Revenue from operations grew ₹670 crore compared with Q1 FY2026. Profit before tax (PBT) increased from ₹733 crore to ₹1,180 crore over the same period, while profit after tax (PAT) rose from ₹545 crore to ₹902 crore.
On a sequential basis, revenue fell 70.8% from the Q4 FY2026 level of ₹10,560 crore. That preceding quarter’s revenue was substantially higher than any other quarter in the available series. The Q1 FY2027 revenue returned to a scale comparable with the year-earlier quarter, and the year-on-year comparison provides the clearest view of the business’s growth.
For Q1 FY2027, the company reported the following major expense items:
Other expenses rose 11.9% from ₹385 crore in Q1 FY2026, a slower increase than the 27.8% revenue growth. Finance costs were ₹6 crore, compared with ₹3 crore in the prior-year quarter and ₹23 crore in the immediately preceding Q4 FY2026.
The PBT margin (PBT as a percentage of revenue from operations) widened to 38.3% from 30.4% a year earlier. The PAT margin moved to 29.3% from 22.6%. The effective tax rate was 23.6% (₹278 crore tax on PBT of ₹1,180 crore), down from 25.6% (₹188 crore on ₹733 crore) in Q1 FY2026.
Divi's Laboratories reported strong Q1 FY27 results, with consolidated total income rising 24% YoY to ₹3,144 Cr and PAT surging 65% to ₹902 Cr, driven by robust revenue growth in its core API and intermediates business. On a standalone basis, revenue from operations grew to ₹2,974 Cr from ₹2,357 Cr YoY, while PAT increased to ₹891 Cr from ₹557 Cr. Management highlighted a forex loss of ₹7 Cr for the quarter, compared to a gain of ₹39 Cr in the prior year, which impacted profitability. The company also strengthened its leadership by appointing two senior management personnel in procurement roles, effective August 1, 2026, signaling a focus on supply chain and operational efficiency.
Category: Manufacturing
Divi's is a leading manufacturer of Generic APIs globally, offering over 30 commercial products and focusing on large-scale production.
Category: B2B Services
Provides custom synthesis contract manufacturing services for APIs and intermediates to large pharmaceutical companies, handling high-potency compounds and high-energy reactions.
Category: Manufacturing
Supplies a comprehensive range of carotenoids and market-targeted vitamins for the nutritional, pharmaceutical, food/beverage, and feed industries.
Core Thesis: The company leverages its manufacturing expertise and R&D capabilities across its business segments to serve global pharmaceutical and nutraceutical markets.
• Sustainable Chemistry and Process Improvement: Divi's Laboratories emphasizes sustainable chemistry and continuous process improvement to enhance lifecycle efficiency in its operations. • Scalable Manufacturing and Capacity Expansion: The company employs a scalable manufacturing approach, allowing for capacity expansion aligned with demand to maximize efficiency in API production. • Global Regulatory Compliance and Quality Assurance: Rigorous quality assurance and control are maintained by a large team, ensuring compliance with global regulatory standards through advanced analytical labs and multiple facility approvals. • Long-term Global Partnerships: The company maintains several global partnerships focused on secure environments for proprietary processes, on-time supply, intellectual property protection, and process integrity.